Viral Vector Manufacturing Success Stories: Onboarding to GMP Production

Join this webinar to learn how to mitigate risk in viral vector manufacturing with tailored solutions and a flexible approach. Discover how unique and transferable technical capabilities in multiple viral vector types can significantly accelerate a development path and future-proof gene therapy products.

The featured experts will walk the attendees through the customer journey at Oxford Biomedica from client onboarding to the successful manufacture of adeno-associated virus (AAV) and lentiviral vectors. They will share success stories of optimized production processes and successful transfer into good manufacturing practice (GMP). Attendees will also hear about end-to-end automation of analytical assays and computer-aided biology strategies to enhance the development, bioprocessing and characterization of viral vectors for gene therapies.

A live Q&A session will follow the presentation, offering attendees a chance to pose questions to the team of experts.

Join this webinar to learn about successful case studies in viral vector manufacturing that use tailored solutions and a flexible approach.

Speakers

Amy Barker, PhD, Principal Scientist, Process Development, Oxford Biomedica

Amy Barker, PhD, is a Principal Scientist at Oxford Biomedica in the Process Development department. Her team is responsible for the initial onboarding of new client products to Oxford Biomedica, designing and performing initial feasibility studies tailored to client needs. These studies involve screening of multiple genomes, plasmid ratio assessments including Design of Experiment (DoE) strategies, and platform performance assessments with relevant analytical assays performed in both indicator cells and target primary cells. Prior to joining Oxford Biomedica, Dr. Barker gained extensive postdoctoral experience in a variety of areas, specializing in applying her understanding of cell and molecular biology to improving human health.

Message Presenter

Andre Raposo, PhD, Director, Innovation Department, Oxford Biomedica

Andre Raposo, PhD, is a Director at Oxford Biomedica in the Innovation department. He leads a group of scientists delivering cutting-edge research in the field of cell and gene therapy supported by computer-aided biology and high-throughput automation. He has extensive experience in technology development, upstream process development, DoE strategies, analytical development, robotics and associated regulatory compliance. Prior to Oxford Biomedica, Dr. Raposo worked within the Transduction Sciences CGT Platform CMC at GSK. Dr. Raposo holds a PhD from the University of Oxford and specialized in the understanding of host restriction factors controlling HIV replication and the mechanisms leading to HIV persistence and latency during his postdoc at the University of California San Francisco and the George Washington University in the USA.

Message Presenter

Hannah Boss, Director, Head of Quality Control, Oxford Biomedica

Hannah Boss is the Interim Head of Quality Control with responsibility for product quality testing, stability, contamination control and analytical method lifecycle management. She has 16 years of industry experience including roles in research, analytical development and quality control. Prior to Oxford Biomedica, Hannah was the head of Quality Control Molecular Biology for Homology Medicines, Inc. Hannah’s previous experience includes roles of increasing responsibility at Genzyme Corporation and bluebird bio. Hannah holds a BS degree in Biology from the University of Massachusetts Amherst and an MS degree in Biotechnology from Worcester State University.

Message Presenter